Medications for Alcohol Use Disorder: Unfilled Prescriptions and Treatment Trajectories

治疗酒精使用障碍的药物：未配处方和治疗轨迹

基本信息

批准号：
10598575
负责人：
HAIDEN A. HUSKAMP
金额：
$ 81万
依托单位：
HARVARD MEDICAL SCHOOL
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-07-01 至 2025-03-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10598575
关键词：
Accidental Injury Acute Address Adherence Admission activity Alcohols Caring Characteristics Chronic Clinical Data Data Set Deductibles Diagnosis Diffuse Disulfiram Drug Prescriptions Education Effectiveness Electronic Health Record Emergency department visit Enzymes Failure Familiarity Fill-It Future Household Income Individual Injury Insurance Insurance Carriers Intervention Interview Laboratory Finding Lead Link Liver Liver Cirrhosis Liver diseases Measures Medical Medicine Mental disorders Methods Morbidity - disease rate Naltrexone Outcome Outpatients Patients Perception Persons Pharmaceutical Preparations Pharmacotherapy Physicians Play Policies Policy Maker Population Practice Management Process Provider Psychiatrist Qualitative Methods Readiness Relapse Reporting Research Role Services Specialist Structure Time Toxicology Visit Woman Writing acamprosate addiction alcohol use disorder clinical training clinically relevant demographics design efficacious treatment evidence base experience falls health plan improved indexing insight male medication compliance men mortality practice setting preference primary care provider provider factors screening, brief intervention, referral, and treatment social stigma therapy design uptake

项目摘要

PROJECT SUMMARY: Many individuals with alcohol use disorder (AUD) receive no treatment, including evidence-based pharmacotherapies. Previous research on AUD medication use has primarily relied on claims data, and thus focuses on only a portion of the AUD medication treatment process (i.e., filled prescriptions). Using only claims data, it is not possible to distinguish the characteristics of individuals who do not receive a prescription from a clinician from those who receive one but do not fill it. It is also not possible to understand how medication prescriptions and fills fit into the trajectory of AUD treatment received. To design practice and policy interventions that will improve AUD medication use, clinicians and policy makers need to understand who “falls off” at each point in the treatment process. We propose to use a dataset from a large national insurer with linked claims and electronic health record (EHR) data for the period 2010-2023, as well as interviews of AUD providers, in a mixed methods study. The linked data will allow us to observe written prescriptions for each patient as well as whether or not the prescriptions were filled. The linked data will also allow us to incorporate clinically relevant information available in EHRs but not claims. Using these data, we will: 1) For individuals diagnosed with AUD, identify patient and provider characteristics associated with being prescribed an AUD medication and the time from index AUD encounter to prescription; 2) For individuals diagnosed with AUD who are prescribed an AUD medication, identify patient and prescriber characteristics associated with filling the prescription and with time to prescription fill; and 3) Identify trajectories of AUD care that incorporate information on prescriptions written for individuals diagnosed with AUD, and examine the association between different treatment trajectories and indicators of subsequent relapse and injury. The study's mixed methods approach, including semi-structured interviews of providers who treat AUD about the factors that influence their AUD medication prescribing decisions, will allow a more nuanced examination of AUD medication prescribing than quantitative analyses alone allow. The findings will help pinpoint where in the treatment process different types of people fall out of treatment and how different treatment trajectories are associated with relapse and injury, informing future intervention and policy design.

项目摘要：许多患有酒精使用障碍 (AUD) 的人没有接受治疗，包括先前对 AUD 药物使用的研究主要依赖于声明。数据，因此仅关注 AUD 药物治疗过程的一部分（即配药）。仅使用索赔数据，无法区分未收到索赔的个人的特征临床医生开具的处方与那些收到处方但未配药的人之间的关系也是无法理解的。药物处方和配药如何适应 AUD 治疗的轨迹设计实践和方法。改善 AUD 药物使用的政策干预措施，军团和政策制定者需要了解我们建议使用来自大型国家的数据集。拥有 2010-2023 年期间关联索赔和电子健康记录 (EHR) 数据的保险公司，以及在混合方法研究中对 AUD 提供商的访谈链接数据将使我们能够观察书面内容。每个患者的处方以及处方是否已配药也将被链接。允许我们纳入电子病历中可用的临床相关信息，但不使用这些数据。将： 1) 对于诊断为 AUD 的个人，确定与以下情况相关的患者和提供者特征：开出 AUD 药物以及从遇到 AUD 指数到开具处方的时间 2) 对于个人；被诊断患有 AUD 且接受 AUD 药物治疗的患者，确定患者和处方者的特征与配药和配药时间相关；以及 3) 确定 AUD 护理的轨迹其中包含为诊断为 AUD 的个人开具的处方信息，并检查不同治疗轨迹与随后复发和损伤指标之间的关联。研究的混合方法，包括对治疗 AUD 的提供者进行半结构化访谈影响他们 AUD 药物处方决定的因素，将允许更细致地检查 AUD 药物处方比单独的定量分析允许的结果将有助于查明在哪里。治疗过程不同类型的人退出治疗以及治疗轨迹有何不同与复发和伤害相关，为未来的干预和政策设计提供信息。